Company Filing History:
Years Active: 2024
Title: Kevin Kish: Innovator in Antibody Development
Introduction: Kevin Kish is a prominent inventor based in Princeton, NJ (US), known for his significant contributions to the field of biochemistry and pharmacology. He holds a patent that focuses on innovative solutions for factor XIa inhibitors, which are crucial in the development of antithrombotic therapies.
Latest Patents: Kevin Kish's patent, titled "Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof," presents novel antigen binding peptides, including antibodies and antibody fragments. These peptides specifically bind to selective FXIa inhibitors and dual inhibitors of FXIa and plasma kallikrein. The invention also outlines methods for reducing the antithrombotic effect of FXIa inhibitors by administering a pharmaceutically effective dose of the antigen binding peptides. Additionally, it provides detection reagents and methods for measuring the levels of FXIa inhibitors in biological samples.
Career Highlights: Kevin Kish has made significant strides in his career, particularly through his work at Bristol-Myers Squibb Company. His research and innovations have contributed to advancements in therapeutic strategies aimed at improving patient outcomes in anticoagulation therapy.
Collaborations: Throughout his career, Kevin has collaborated with esteemed colleagues, including Joseph M. Luettgen and Lumelle A. Schneeweis. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in the pharmaceutical industry.
Conclusion: Kevin Kish's work exemplifies the impact of innovative thinking in the field of biochemistry, particularly in the development of therapies that address critical health issues. His contributions continue to influence the landscape of antithrombotic treatments and showcase the importance of research and collaboration in scientific advancements.